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Objective: Stem cell therapy can facilitate cardiac repair in infarcted myocardium, but the optimal cell type
remains uncertain. We conducted a randomized, blind, and placebo-controlled comparison of autologous bone
marrow mononuclear cell and mesenchymal stem cell therapy in a large-animal model of chronic myocardial
infarction.
Methods: Eleven weeks after coronary ligation, 24 dogs received intramyocardial injections of mononuclear
cells (227.106  32.106 cells), mesenchymal stem cells (232.106  40.106 cells), or placebo (n ¼ 8 per group).
Cardiac performance and remodeling were assessed up to 16 weeks’ follow-up.
Results: At echocardiographic analysis, the wall motion score index showed a sustained improvement after
mononuclear cell transfer (from 1.8  0.1 to 1.5  0.07) and a moderate late improvement after mesenchymal
stem cell transfer (from 1.9 0.08 to 1.7 0.1). After mononuclear cell transfer, end-systolic elastance increased
(from 2.23  0.25 to 4.42  0.55 mm Hg/mL), infarct size decreased (from 13%  0.67% to 10%  1.17%),
N-terminal B-type natriuretic propeptide level decreased (from 608 146 to 353 118 pmol/L), and relative wall
area and arterial density increased. Vascular endothelial growth factor receptor 2 expression was upregulated in
the border zone. No change in cardiac contractility or histologic parameters was noted in the mesenchymal stem
cell group.
Conclusion: In a canine model of chronic myocardial infarction, bone marrow mononuclear cell transfer is su-
perior to mesenchymal stem cell transfer in improvement of cardiac contractility and regional systolic function
and reduction in infarct size and plasma N-terminal B-type natriuretic propeptide level. Functional improvement
is associated with a favorable angiogenic environment and neovascularization.
Acquired Cardiovascular Disease Mathieu et alCell therapy with bone marrow–derived stem cells has been
investigated to facilitate cardiac repair after ischemic injury
with beneficial effects.1 Most clinical studies use the entire
bone marrow mononuclear cell (BMNC) fraction2-7 with
the rationale that the functional effect depends on the equi-
librium between the multiple cell types, and by using a large
panel of precursors, no potentially beneficial cell type is
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blind and placebo-controlled trials in patients with acute
myocardial infarction (MI),4,6 and this strategy is applied
also in ongoing trials in patients with chronic ischemic heart
failure. On the other hand, culture-expanded mesenchymal
stem cells (MSCs) are characterized by multilineage differ-
entiation potential, notably in cardiomyocytes and endothe-
lial cells.8-11 Moreover, their immunoprivileged features
might allow allogenic use.12 Although this might offer sev-
eral advantages over the mononuclear cell fraction, there are
no data comparing the efficacy of both cell types in chronic
models of MI. In addition, previous experimental studies
only used a limited set of load-dependent functional surro-
gate end points. Thus far, an integrative assessment of inter-
ventional outcome on left ventricular (LV) function,
contractility, infarct size, and remodeling is lacking.
Therefore we conducted a randomized, investigator-
blinded, and placebo-controlled study with multimodality
assessment of autologous BMNC and MSC therapy in
a canine model of chronic MI.rgery c September 2009
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Ang ¼ angiopoietin
BMNC ¼ bone marrow mononuclear cell
Ct ¼ cycle threshold
Ees ¼ end-systolic elastance
LV ¼ left ventricular
MI ¼ myocardial infarction
MRI ¼ magnetic resonance imaging
MSC ¼ mesenchymal stem cell
RTQ-PCR ¼ real-time quantification polymerase
chain reaction
SDF-1 ¼ stromal cell–derived factor 1
TEK ¼ angiopoietin 1 and 2 receptor
VEGF ¼ vascular endothelial growth factor
VEGFR ¼ vascular endothelial growth factor
receptor
WMS ¼ wall motion score
MATERIALS AND METHODS
The study was approved by the institutional ethics committee for animal
research, and all animals received humane care in compliance with the
‘‘Guide for the care and use of laboratory animals’’ (http://www.nap.edu/
catalog/5140.html).
Animals and MI
MI was caused by ligation of the left circumflex coronary artery, its mar-
ginales, or both in dogs (CEDS, Me´zilles, France; 13.7  0.4 kg; 10–15
months old). After intravenous premedication with 0.1 mg/kg of midazolam
and 0.1 mg/kg sufentanil, anesthesia was induced with 3 to 4 mg/kg intrave-
nous propofol and maintained with isoflurane (1.5%–2%). Animals were
ventilated with a fraction of inspired oxygen of 1, a respiratory rate of 12
breaths/min, and a tidal volume of 12 to 15 mL/kg. Lactate–Ringer’s solu-
tion was infused at 10 mL $ kg1 $ h1, and sufentanil was infused at 1 mg $
kg1 $ h1. After a left thoracotomy, MI was created by means of surgical
ligation of the left circumflex artery, its marginales, or both, with special
care to obtain the same infarction extent despite anatomic specificities. Se-
vere ventricular arrhythmias during and after the procedure were treated
with 2 to 4 mg/kg intravenous lidocaine over a period of 2 minutes followed
by an infusion of 75 mg $ kg1 $ min1. After surgical intervention, bupre-
norphine (10 mg/kg administered intramuscularly 3 times daily) and cepha-
lexin (20 mg/kg administered subcutaneously twice daily) were
administered for 48 hours. Only animals with an echocardiographic wall
motion score (WMS) index of greater than 1.6 one week after ligation
entered the study (n ¼ 24).
Bone Marrow Cell Preparation
Autologous bone marrow MSCs, harvested in the iliac crest of each dog
the day of coronary ligation, were culture expanded as described previ-
ously13; the samples were immediately treated with a mix (1:1) of dimethyl
sulfoxide and hydroxyethyl starch solution (6% final concentration) and
frozen at80C until processing. Four weeks after ligature, samples were
thawed, and marrow was plated onto T75 collagen-treated culture flasks
in standard growth media to remove nonadherent cells. The plastic-attached
cells were culture expanded for 3 to 5 weeks with media containing DMEM
(Invitrogen, Merelbeke, Belgium), 20% fetal bovine serum (Hyclone, Lo-
gan, Utah), 100 mmol/L L-ascorbic acid (Sigma–Aldrich, St Louis, Mo),
and 5 mg/mL human leukemia inhibitor factor (Sigma–Aldrich). After ex-The Journal of Thoracic and Cpansion, MSCs were frozen at 80C until use. Before injection, cells
were washed with the culture medium and phosphate-buffered saline. The
day of injection, autologous BMNCs prepared from the bone marrow har-
vested the day of injection were enrichedwith the use of the Ficoll–Hypaque
centrifugation procedure (Lymphoprep, Oslo, Norway). Marrow was di-
luted 1:4 with Hank’s medium and centrifuged on a Ficoll density gradient
(at 600g for 30 minutes) to isolate the mononuclear cells. The placebo
medium was phosphate-buffered saline.
Preference was given to the use of canine antibodies to characterize the
cells. However, when canine antibodies were commercially unavailable, hu-
man antibodies were used. More specifically, canine MSCs and BMNCs
were analyzed by means of FACS after incubation with anti-human
CD44, CD166, CD14, CD13, CD90, CD105, CD73 (SH3), CD71 (SH3),
CD45, Stro-1, CD133, CD117, HLA class I, and HLA class II antibodies
conjugated with fluorescein isothiocyanate or phycoerythrin. The CD14
and CD44 antibodies are known to cross-react with dog cells. Dog cells
were also analyzed with anti-canine CD34 antibodies conjugated with phy-
coerythrin. Viability was analyzed by using Trypan blue staining.
Experimental Design
Animals were randomized into 3 groups (n ¼ 8 per group): the placebo,
BMNC, and MSC groups. Cells were injected 11.2 0.63 weeks after cor-
onary ligation. A total volume of 4 mL of cells or placebo was injected
through a thoracotomy tangentially into the infarct and border zones over
approximately 20 injections of approximately 0.2 mL with a 27-gauge nee-
dle. Cells were injected in parallel lines extending from healthy tissue to the
opposite border zone (until 1.5 cm in healthy tissue). Lines were between
0.5 and 1 cm apart, and on the lines, injection points were also between
0.5 and 1 cm apart. A total of 227  32 3 106 MSCs and 232  40 3
106 BMNCs were injected. Echocardiographic analysis was performed be-
fore MI and repeated 1 and 2 weeks before cell injection (baseline), as well
as 8, 9 (9 weeks), and 16 weeks after cell injection. Pressure–volume loops
were determined 1 week before cell injection (baseline) and at 9 weeks’ fol-
low-up. Cardiac magnetic resonance imaging (MRI) was performed at base-
line and 16 weeks’ follow-up. Venous blood samples were collected before
cell injection and 2, 4, 6, 8, and 16 weeks after cell injection. At 17 weeks’
follow-up, dogs were killed, and tissue samples were taken for postmortem
analyses.
The following end points were analyzed. Cardiac contractility was as-
sessed from the LV end-systolic elastance (Ees), regional LV function
was assessed from the WMS index at echocardiographic analysis, infarc-
tion size was measured by using late enhancement imaging at MRI, the hu-
moral marker of LV dysfunction was assessed by means of plasma
concentration of N-terminal B-type natriuretic propeptide (NT-proBNP),
remodeling was assessed based on the relative LV wall area at macro-
morphometry, neovascularization was assessed based on vascular density
at immunohistochemistry, and transcriptional profile of angiogenic signal-
ing was assessed by means of real-time quantification polymerase chain
reaction (RTQ-PCR).
Echocardiographic Analysis
Echocardiographic analysis (Vivid 5; GE, Brussels, Belgium) was per-
formed in awake dogs, with recordings in standard windows according to
recommendations.14 TheWMS index was assessed by using the 16-segment
model.15 All images were recorded and analyzed offline as a consensus of
2 experienced ultrasonographers (KM and JB) blinded to the treatment
assignment.
Pressure–Volume Loops
Pressure–volume loops were obtained through catheterization in anes-
thetized closed-chest dogs. They were generated with a LV conductance
catheter (Millar Instruments, Houston, Tex) and IOX software (EMKA
Technologies, Paris, France). Ees of the left ventricle, a load-independentardiovascular Surgery c Volume 138, Number 3 647
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cava during respiratory arrest. A linear regression analysis of the end-sys-
tolic pressure–volume points during transient preload reduction determined
the slope (Ees) of the end-systolic pressure-volume relationship.16
MRI
Infarct size was assessed by using the 1.5-Tesla clinical MRI scanner
(Achieva 1.5T; Phillips Best, The Netherlands) with a 2-element phased
array coil placed over the chest (Sense Flex–M Coil; Philips, Brussels, Bel-
gium). After contrast-enhanced images were acquired, raw images were
processed by means of manual outlining of the endocardial–epicardial
and infarct borders. Total infarct volume was calculated as the summation
of the contrast-enhanced volumes from all contrast-enhanced MRI images.
Relative MI size was determined as the ratio of infarct volume to LV wall
volume times 100.
Blood Biology
NT-proBNP levels were measured by means of enzyme-linked immuno-
sorbent assay (VETSIGN Canine CardioSCREEN Nt-proBNP Test
VC4010; Guildhay Limited, Guildford, England).
Macromorphometry
After death, hearts were sectioned into 8-mm-thick short-axis slices and
digitally photographed.Byusing image J (National Institute ofHealth, http://
rsb.info.nih.gov/ij/), LVendocardial and epicardial borderswere traced.Rel-
ative LV wall area was evaluated in apical, mid, and basal slices as (Epicar-
dial areaEndocardial area)3100/ Epicardial area and averaged.
Immunohistochemistry
Paraffin-embedded formalin-fixed specimens from the infarct, border,
and remote zones were prepared in 5-mm-thick sections. Endothelial cells
were stained with anticaveolin-1 antibody (sc-984; Santa Cruz Biotechnol-
ogy, Inc, Santa Cruz, Calif). Sections incubated with nonimmune serum
were used as negative controls. Microvessels (diameter<20 mm) were
counted on 10 different 3400 randomly selected fields from each zone,
and the density of arterial vessels (diameter>20 mm) was semiquantified
by using a relative gradient between 0 and 2.
RTQ-PCR
Total RNA of snap-frozen specimens (placebo and MSC groups, n ¼ 7;
BMNC group, n ¼ 6) from the infarct, border, and remote zones of each
group was extracted with Trizol (Invitrogen), and its concentration was ad-
justed to 0.25 mg/mL. After first-strand cDNA synthesis, Sybr Green RTQ-
PCR was performed (Icycler; Bio-Rad Laboratory, Nazareth, Belgium).
Primers were designed to recognize canine cDNA sequences of vascular en-
dothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2),
angiopoietin 1 (Ang1) and Ang2, their receptor (TEK), and stromal cell–de-
rived factor 1 (SDF1). Abbelson was used as a housekeeping gene. Statis-
tical analysis was carried out by using the differences between the cycle
thresholds (Ct;DCt¼ Ct gene of interestCt housekeeping gene). Relative
gene expression values were obtained by using theDDCt method (DCt sam-
pleDCt calibrator)with placebo as the calibrator. The conversion of DDCt
to relative gene expression is a result of fold induction: 2DDCt.17
Statistics
All continuous values are expressed as means  standard error of the
mean, all reported P values are 2-sided, and statistical significance is as-
sessed at the 5% level. The normality of distribution was tested with
a Shapiro–Wilk test. For normal data, differences were tested by using 2-
way analysis of variance (group and time) for repeated measures with an in-
teraction term, followed by Scheffe post-hoc tests when overall significance
was detected. When the Shapiro–Wilk test failed, differences within the648 The Journal of Thoracic and Cardiovascular Sugroups (repeatedmeasures) were analyzed by using a Friedman test, and dif-
ferences between groups were analyzed by using a Kruskal–Wallis test. For
baseline characteristics, macromorphometry, histologic data, and RTQ-
PCR, differences between groups were tested by using 1-way analysis of
variance, followed by Scheffe post-hoc tests when overall significance
was detected. When the Shapiro–Wilk test failed, differences between
groups were tested by using a Kruskal–Wallis test.
RESULTS
Baseline Characteristics
BMNCs showed uniformly CD14 and CD44 markers,
whereas only 3% of cells were CD34þ and 3% were
CD166þ. MSCs were positive for CD166 (42%) and
CD44 (84%). Canine MSCs and BMNCs were negative
for all the other markers tested, but a lack of cross-reactivity
might explain the negative results. Morphology of BMNCs
and MSCs was comparable with that of similar cells in other
species. The percentage viability was 99%  0.05% for
BMNCs and 98.4%  0.51% for MSCs.
Coronary ligation resulted in a mean infarct size of 12.9%
 0.7%, a mean WMS index of 1.8 0.06, and a mean Ees
of 2.3 0.26 mm Hg/mL. Cardiac function baseline charac-
teristics before cell injection, such as infarct size (placebo
group, 12%  1% enhanced area; BMNC group, 13% 
2% enhanced area; MSC group, 14%  1% enhanced
area; P ¼ .460), Ees (placebo group, 2.7  0.2 mm Hg/
mL; BMNC group, 2.2  0.3 mm Hg/mL; MSC group,
2.1 0.7 mmHg/mL; P¼ .339), andWMS (placebo group,
1.7  0.1; BMNC group, 1.8  0.1; MSC group, 1.9  0.1;
P ¼ .571), were not different between groups.
Effects of Cell Therapy on Cardiac Function
Ees increased after BMNC transfer but remained un-
changed in the placebo and MSC groups (Figure 1). The
volume–axis intercept of the end-systolic pressure–volume
relationship remained unchanged in the 3 groups (data not
shown). Bidimensional echocardiographic analysis revealed
a sustained reduction in the WMS index in the BMNC group
at 9 and16weeks’ follow-up comparedwith the value at base-
line. In contrast, only a mild late decrease in the WMS index
was noted in the MSC group, whereas no change was ob-
served in the placebogroup (Figure 2).No significant changes
in the LV ejection fraction were noted (change:1.2% 3%
in the placebo group,þ3.4% 3% in the BMNC group, and
þ0.4% 2% in theMSC group). Nevertheless, improved re-
gional wall motion and contractility after cell therapy was
associatedwith a decrease in plasmaNT-proBNP levels in the
BMNC group, whereas no changes were observed in the
placebo and MSC groups (Figure 3).
Effects of Cell Therapy on Infarct Size and LV
Remodeling
As shown in Figure 4, infarct size, as assessed from the
extent of late hyperenhancement atMRI, increased in the pla-
cebo group and decreased in the BMNC group. No changergery c September 2009
Mathieu et al Acquired Cardiovascular DiseaseFIGURE 1. Left ventricular contractility. A, Representative pressure–volume loops during vena caval occlusion in each group at baseline and 9 weeks’
follow-up. Note the increased end-systolic elastance (Ees) after bone marrow mononuclear cell (BMNC) transfer. B, End-systolic elastance at baseline
and 9 weeks’ follow-up in the placebo, bone marrow mononuclear cell, and mesenchymal stem cell (MSC) groups.A
C
Dwas observed in theMSCgroup. Relative LVwall area, mea-
sured postmortem by means of macromorphometry, was
higher in the BMNC group compared with that seen in the
placebo and MSC groups (Figure 5).
Vascular Density and Gene Expression Analysis
The density of microvessels (diameter<20 mm) was sim-
ilar between the groups (data not shown). However, a higher
density of vessels over 20 mmwas observed in the infarct tis-
sue after BMNC transfer comparedwith that seen in theMSC
group (Figure 6). In addition, VEGFR2message levels were
increased and TEK message levels tended to increase in the
border zone after BMNC transfer compared with that seen
in other groups (Figure 7, A and B). SDF1 message levels
tended to be higher in the remote and border zones for the
FIGURE 2. Left ventricular regional systolic function. The wall motion
score (WMS) index at echocardiographic analysis at baseline and 9 and 16
weeks’ follow-up in the placebo, bone marrow mononuclear cell
(BMNC), and mesenchymal stem cell (MSC) groups is shown.The Journal of Thoracic and CBMNC group compared with those seen in the MSC group
(Figure 7, C). There were no changes in expression of
VEGF, VEGFR1, Ang1, and Ang2 (data not shown). Note,
TEK message levels were inversely related to WMS index
(Figure 7, D), and the SDF1 levels correlated with both
VEGFR2 (r¼ 0.55, P<.001) and TEK (r¼ 0.51, P<.001).
DISCUSSION
The present randomized, blinded, and placebo-controlled
large-animal studyusedmultimodality assessment to compare
the efficacy of autologous BMNCs and nonmodified MSCs
for the treatment of chronic MI. Direct myocardial injections
of BMNCs were associated with superior improvement in
FIGURE 3. Time course of N-terminal B-type natriuretic propeptide
(BNP). Plasma N-terminal B-type natriuretic propeptide levels decreased
at 2, 4, 6, and 8 weeks’ follow-up in the bone marrow mononuclear cell
(BMNC) group compared with baseline values and remained unchanged
in the other 2 groups.P values are shown versus baseline values.MSC, Mes-
enchymal stem cell.ardiovascular Surgery c Volume 138, Number 3 649
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duction in infarct scarring, compared with that seen after
MSCs. This functional improvement was paralleled by re-
verse remodeling and neovascularization.
Among various autologous cell types, most of the preclin-
ical and clinical trials have tested BMNCs.1-6 Their choice
was based on the postulate that by using the entire mononu-
clear fraction, no potentially beneficial cell type was omitted
FIGURE 4. Left ventricular infarct size. A, Infarct size (myocardial infarction [MI] as a percentage) determined by means of contrast-enhanced magnetic
resonance imaging at baseline and 16 weeks’ follow-up in the placebo, bone marrow mononuclear cell (BMNC), and mesenchymal stem cell (MSC) groups is
shown. B, Left, Representative example before and after bonemarrowmononuclear cell transfer. Note a reduction in the late enhancement at follow-up (yellow
arrow). Right, Late enhancement intensity remained unchanged in the placebo-treated animal, and infarct size increased (white arrow).
FIGURE 5. Left ventricular (LV) remodeling. A, Relative left ventricular wall area at macromorphometry in the placebo, bone marrow mononuclear cell
(BMNC), and mesenchymal stem cell (MSC) groups is shown. B, Representative macromorphometric analysis in the placebo, bone marrow mononuclear
cell, and mesenchymal stem cell groups is shown. Wall thickness in the infarct zone (yellow arrows) and in the border zone (black arrows) is greater in
the bone marrow mononuclear cell–treated animal compared with that seen in the placebo-treated and mesenchymal stem cell–treated animals.
650 The Journal of Thoracic and Cardiovascular Surgery c September 2009
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librium between cell types. This postulate is supported by
the cellular crosstalk between multiple cell types required
during embryonic vascular development.18 Regardless of
the controversy over whether transplanted BMNCs do1 or
do not19 transdifferentiate, a number of preclinical and clin-
ical studies have demonstrated that administration of
BMNCs can improve cardiac function or perfusion early af-
ter MI2-4,6 or lead to reduction in infarct size.5 Nevertheless,
the potential of bone marrow cells in the setting of ischemic
congestive heart failure was studied only in small, non-
randomized clinical trials and remains unknown.20-23
An alternative to the mononuclear cell fraction is the en-
richment for a specific cell population, such as hemato-
poietic cells or MSCs. In both strategies the hypothetical
benefit is the retention of cells with well-defined biologic
properties in a much higher dose that could be achieved if
given as a part of the mononuclear cell fraction. MSCs ap-
pear to offer an additional advantage by displaying multili-
neage potential11 and cytokine production in response to
FIGURE 6. Vascular density. Upper panels show representative immunostaining with anticaveolin 1 in a bone marrow mononuclear cell (BMNC; A)– and
mesenchymal stem cell (MSC; B)–treated animal. (Original magnification 340). White arrows show vessels larger than 20 mm. C, Semiquantitative assess-
ment of arterial vessels (>20 mm) density in the infarct zone of the placebo, bone marrow mononuclear cell, and mesenchymal stem cell groups.
FIGURE 7. Angiogenic factors. A, B, and C, Relative gene expression of vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 and an-
giopoietin-2 receptor (TEK), and stromal cell–derived factor 1 (SDF1) in infarct (MI), border (MB), and remote (MR) areas of the placebo, bonemarrowmono-
nuclear cell, and mesenchymal stem cell groups. The mean value for the placebo group is represented as 1, and the values of treated dogs are adjusted
accordingly. D, Scatterplots of TEK-relative gene expression in the border zone (y-axis) versus the WMS index (x-axis). The regression equation, its coef-
ficient of correlation (r), and significances are shown.
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makes them an ideal candidate for the regenerative therapies
with a potential off-shelf use.12 In a rat or swine model of
myocardial ischemia–reperfusion injury, allogenic MSCs
contributed to neovascularization and myogenesis and im-
proved LV ejection fraction.10,24 In a dog model of chronic
MI, catheter-based injection of these cells led to functional
improvement in parallel to increased capillary density de-
spite the absence of cardiac markers in the labeled cells.8
Similar beneficial effects were observed in a pig study of
acute MI, in which MSC transfer resulted in improved re-
gional and global LV function and reduced infarct size.25
It remains unclear which of these cell fractions has the
higher regenerative potential in the infarcted myocardium.
Only few studies directly compared various cell types. In
a porcine model of ischemia and reperfusion, Moelker and
colleagues26 compared BMNCs with unselected bone mar-
row. The authors found a greater reduction in infarct size
with BMNCs without improvement of regional or global
LV function. Kawamato and associates27 demonstrated
that purified CD34þ cells had better biologic and functional
effects than BMNCs, even if the dose of BMNCs was ad-
justed to contain an equivalent number of CD34þcells. How-
ever, cell injection was performed immediately after
coronary ligation, and it is unclear to what extent these
data are relevant to the chronically infarcted myocardium.
To the best of our knowledge, our study is the first head-
to-head comparison of BMNCs and culture-expanded
MSCs in the setting of chronic MI. In addition to the pla-
cebo-controlled and blinded design, we used multimodality
functional assessment, including LV Ees, an invasive load-
independent index of cardiac contractility, in a large-animal
model of the chronically infarcted myocardium. It is interest-
ing to note that neither therapy had a significant effect on the
global and load-dependent indices of LV function. This
might be at least partially related to the modest infarction
size with mild reduction in global LV ejection fraction. In
this setting direct assessment of infarction size by means
of MRI might be superior to assessment of ejection fraction
in tracking the changes in response to cell therapy.5 In this
regard our data indicate that myocardial injection of BMNCs
is associated with greater improvement in cardiac contractil-
ity and regional LV systolic function, reduction of infarct
size, and reverse remodeling compared with autologous
MSCs. The beneficial effects on both remodeling and
function resulted in reduction of NT-proBNP levels. The
superior effects of BMNCs were associated with an upregu-
lation of VEGFR2 and TEK expression in parallel with in-
creased arterial density. It is also interesting to note that
although nonsignificant trends were observed in SDF1
expression, its message levels correlated with both VEGFR2
and TEK. Given the interplay between VEGF signaling
and SDF1 in adult neovascularization,28 this suggests
that BMNC-induced reversed remodeling and improved652 The Journal of Thoracic and Cardiovascular Sperformance of the chronically infarcted myocardium might
be mediated by a favorable proangiogenic environment and
increased neovascularization after BMNC administration.
This favorable angiogenic paracrine effect might be attrib-
uted in part to the larger amount of CD14þ cells in the
nonmodified BMNC fraction and their effects on neovascu-
larization.29 Yet the potential effect of BMNC cell delivery
on mobilization or recruitment of circulating or tissue-resid-
ing progenitors and their contribution to regenerative re-
sponse should be further addressed.
These observations have several implications for the
framework of future preclinical and clinical studies. On the
one hand, they support future clinical studies with BMNCs
in patients with ischemic cardiomyopathy. On the other
hand, they challenge the use of nonmodified MSCs as
a cell product for regenerative strategies in the setting of
the chronically infarcted myocardium. Although statistically
significant, the effect of MSC transfer on regional LV func-
tion remained modest and did not translate either into
improved contractility or reduction of the infarct size or sys-
temic levels of NT-proBNP. The lack of functional effects
might be related to the failure to induce transcriptional acti-
vation of angiogenic signaling. Our data are thus in contrast
with those of experimental studies showing a reduction in in-
farct scarring, increased thickness of myocardium, and pro-
gressive restoration of contractile function after MSC
transplantation.8,25,30 These studies mostly used allogenic
MSCs, often administered early after the infarction, and re-
cruitment of residing stem cells caused by local inflammatory
response has been hypothesized as one of the potential mech-
anisms underlying the regenerative process.8,25 In addition,
our model was characterized by a moderate infarct size,
and greater benefit from MSCs could be expected in models
withmore compromisedLV function.22,25 On the other hand,
our data are consistent with those of several studies in which
sustained or long-term benefit after injection of MSCs was
not observed.10,13,24 In addition, themodest effect of nonmo-
dified MSCs supports the development of new strategies to
test the hypothesis that guidance ofMSCs toward the cardiac
lineage might lead to more robust effects on biologic and
functional repair after chronic MI.13
In conclusion, the present randomized, double-blind, and
placebo-controlled with multimodality comparison demon-
strates that cell therapy with BMNCs is superior to use of
culture-expanded nonmodified MSCs and is associated
with reduced infarction size, as well as improved regional
function and cardiac contractility, in a canine model of
chronic MI. The functional amelioration is associated with
a reduction of NT-proBNP level, reverse remodeling, and
neovascularization in a proangiogenic environment.
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